ArticleBioMed research international2016
Circulating Endocannabinoids and Insulin Resistance in Patients with Obstructive Sleep Apnea.
Article in BioMed research international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 22 citations in OpenAlex.
- Exploring the Role of Polyunsaturated Fatty Acids in Children's Sleep.Biomedicines · 2025Review
- Elevated IGFBP4 and Cognitive Impairment in a PTFE-Induced Mouse Model of Obstructive Sleep Apnea.International journal of molecular sciences · 2025Article
- A Preliminary Integrated Metabolomics Analysis Identifies Retrograde Endocannabinoid Signaling Shift in Severe OSA Patients.Sleep & breathing = Schlaf & Atmung · 2025Article
- Non-esterified erythrocyte linoleic acid, arachidonic acid, and subjective sleep outcomes.Prostaglandins, leukotrienes, and essential fatty acids · 2023Article
- Pathophysiological mechanisms and therapeutic approaches in obstructive sleep apnea syndrome.Signal transduction and targeted therapy · 2023Review
- CB1 receptor antagonist rimonabant protects against chronic intermittent hypoxia-induced renal injury in rats.BMC nephrology · 2021Article
- Functional Fine-Tuning of Metabolic Pathways by the Endocannabinoid System-Implications for Health and Disease.International journal of molecular sciences · 2021Review
- BIONOTE as an Innovative Biosensor for Measuring Endocannabinoid Levels.Sensors (Basel, Switzerland) · 2021Article
- The Endocannabinoid System as Prognostic Biomarker of the Obstructive Sleep Apnea Morbidity in COVID-19-Recovered Individuals.Sleep and vigilance · 2021Review
- CB1 receptor antagonist rimonabant protects against chronic intermittent hypoxia-induced bone metabolism disorder and destruction in rats.Sleep & breathing = Schlaf & Atmung · 2020Article
- Endocannabinoids and Stroke Prevention: Review of Clinical Studies.Cannabis and cannabinoid research · 2020Review
- The Endocannabinoid System May Modulate Sleep Disorders in Aging.Current neuropharmacology · 2020Review
- Linoleic acid in diets of mice increases total endocannabinoid levels in bowel and liver: modification by dietary glucose.Obesity science & practice · 2019Article
- Profiling plasma N-Acylethanolamine levels and their ratios as a biomarker of obesity and dysmetabolism.Molecular metabolism · 2018Article
- Corrigendum to "Circulating Endocannabinoids and Insulin Resistance in Patients with Obstructive Sleep Apnea".BioMed research international · 2018Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives. The purpose of this study is to investigate the relationship between plasma endocannabinoids and insulin resistance (IR) in patients with obstructive sleep apnea (OSA). Methods. A population of 64 with OSA and 24 control subjects was recruited. Body mass index (BMI), waist circumference, lipids, blood glucose and insulin, homeostasis model of assessment for insulin resistance index (HOMA-IR), anandamide (AEA), 1/2-arachidonoylglycerol (1/2-AG), and apnea-hypopnea index (AHI) were analyzed. Results. Fasting blood insulin (22.9 ± 7.8 mIU/L versus 18.5 ± 7.2 mIU/L, P < 0.05), HOMA-IR (2.9 ± 1.0 versus 2.4 ± 0.9, P < 0.01), AEA (3.2 ± 0.7 nmol/L versus 2.5 ± 0.6 nmol/L, P < 0.01), and 1/2-AG (40.8 ± 5.7 nmol/L versus 34.3 ± 7.7 nmol/L, P < 0.01) were higher in OSA group than those in control group. In OSA group, AEA, 1/2-AG, and HOMA-IR increase with the OSA severity. The correlation analysis showed significant positive correlation between HOMA-IR and AHI (r = 0.44, P < 0.01), AEA and AHI (r = 0.52, P < 0.01), AEA and HOMA-IR (r = 0.62, P < 0.01), and 1/2-AG and HOMA-IR (r = 0.33, P < 0.01). Further analysis showed that only AEA was significantly correlated with AHI and HOMA-IR after adjusting for confounding factors. Conclusions. The present study indicated that plasma endocannabinoids levels, especially AEA, were associated with IR and AHI in patients with OSA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.